Athersys (ATHX) Jumps After Being Granted FDA Orphan Drug Status
- Top 10 News for 10/5 - 10/9: Twitter Names New CEO; Fed Cautious on Hike Amid Global Slowdown; GE Gets New Activist
- Wall Street ends best week of year with slight gain
- DSV to Acquire UTi Worldwide (UTIW) in $1.35B Deal
- SolarWinds (SWI) Commences Review of Strategic Alternatives
- Barclays Downgrades Tesla Motors (TSLA) to Underweight
Athersys, Inc. (Nasdaq: ATHX) spikes on word it was granted FDA orphan drug stats for MPS-1 treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cadiz (CDZI) Comments on Media Reports Following BLM Guidance
- Hertz (HTZ) Shares Ramp to Session Highs Following Lyft News
- AstraZeneca (AZN) Temporarily Pauses Two AZD9291 Combo Trials on Lung Disease Incidences
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!